Initiate Phase 1/2 trial for PBFT02 for frontotemporal dementia with granulin mutations
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Mar 2021
- Due
- 30 Jun 2021
- Checked
- 27 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate Phase 1/2 trial for PBFT02 for the treatment of FTD-GRN in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The 10-Q filed 2021-08-05 said initiation was expected in Q3 2021, and the 2021-11-04 10-Q moved it to Q4 2021, after the first-half 2021 deadline.
-
A Passage Bio, Inc. 10-Q filed 2021-08-05
“We expect to initiate our upliFT-D Trial in the third quarter of 2021” ✓ confirmed on the page
-
A Passage Bio, Inc. 8-K filed 2021-10-04
“First patient enrollment expected in 4Q21” ✓ confirmed on the page
-
A Passage Bio, Inc. 10-Q filed 2021-11-04
“We expect to initiate our upliFT-D Trial in the fourth quarter of 2021” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 1/2 trial for PBFT02 (FTD-GRN)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Passage Bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-PASG-025081 · Corrections policy